PV3B Stock Overview A clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
EyePoint Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for EyePoint Pharmaceuticals Historical stock prices Current Share Price US$8.83 52 Week High US$28.60 52 Week Low US$6.56 Beta 1.51 1 Month Change 7.63% 3 Month Change 16.99% 1 Year Change -54.51% 3 Year Change -28.24% 5 Year Change -36.04% Change since IPO -61.63%
Recent News & Updates
EyePoint Pharmaceuticals, Inc. Appoints Reginald J. Sanders to Its Board of Directors Jan 08
Eyepoint Pharmaceuticals, Inc. Announces First Patient Dosed in Second Global Phase 3 Lucia Clinical Trial of DURAVYU for the Treatment of Wet Age-Related Macular Degeneration Dec 04
New major risk - Revenue and earnings growth Nov 14
Third quarter 2024 earnings released: US$0.54 loss per share (vs US$0.33 loss in 3Q 2023) Nov 09
New major risk - Revenue and earnings growth Nov 02 EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $140.000003 million. Oct 31
See more updates
EyePoint Pharmaceuticals, Inc. Appoints Reginald J. Sanders to Its Board of Directors Jan 08
Eyepoint Pharmaceuticals, Inc. Announces First Patient Dosed in Second Global Phase 3 Lucia Clinical Trial of DURAVYU for the Treatment of Wet Age-Related Macular Degeneration Dec 04
New major risk - Revenue and earnings growth Nov 14
Third quarter 2024 earnings released: US$0.54 loss per share (vs US$0.33 loss in 3Q 2023) Nov 09
New major risk - Revenue and earnings growth Nov 02 EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $140.000003 million. Oct 31
EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $140.000003 million. Oct 30
EyePoint Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Oct 29
New major risk - Revenue and earnings growth Oct 28
EyePoint Pharmaceuticals, Inc. Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU for Diabetic Macular Edema Oct 28
Eyepoint Pharmaceuticals, Inc. Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of Durasert for the Treatment of Wet Age-Related Macular Degeneration Oct 24
Now 22% undervalued Oct 23
EyePoint Pharmaceuticals, Inc. Announces Board Changes Sep 04
Insider recently bought €90k worth of stock Aug 22
New major risk - Revenue and earnings growth Aug 12
New major risk - Shareholder dilution Aug 11
New major risk - Revenue and earnings growth Aug 09 EyePoint Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million. Aug 09
Second quarter 2024 earnings released: US$0.58 loss per share (vs US$0.61 loss in 2Q 2023) Aug 08
New major risk - Revenue and earnings growth Aug 07
New minor risk - Insider selling Aug 06
EyePoint Pharmaceuticals, Inc. Highlights Duravuyu Clinical and Regulatory Progress and Pipeline Innovation At R&D Day 2024 Jun 27
New major risk - Revenue and earnings growth May 10
New major risk - Revenue and earnings growth May 09
First quarter 2024 earnings released: US$0.55 loss per share (vs US$0.56 loss in 1Q 2023) May 09
High number of new directors May 07
New major risk - Shareholder dilution Apr 28
EyePoint Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024 Apr 28
EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board Apr 02
Full year 2023 earnings released: US$1.82 loss per share (vs US$2.74 loss in FY 2022) Mar 08
EyePoint Pharmaceuticals, Inc. Announces Management Changes Mar 05
EyePoint Pharmaceuticals, Inc. Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration Feb 05
Executive Vice-Chairman recently sold €802k worth of stock Jan 26
EyePoint Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Verona Clinical Trial of Eyp-1901 for the Treatment of Diabetic Macular Edema Jan 11
Executive Vice-Chairman recently sold €384k worth of stock Dec 07 EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $200.000002 million. Dec 07
EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $200.000002 million. Dec 06
EyePoint Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $175 million. Dec 05
EyePoint Pharmaceuticals, Inc. Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet Amd Achieving All Primary and Secondary Endpoints Dec 04
New major risk - Revenue and earnings growth Nov 02
Third quarter 2023 earnings released: US$0.33 loss per share (vs US$0.49 loss in 3Q 2022) Nov 02
EyePoint Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 01, 2023 Oct 26
EyePoint Pharmaceuticals, Inc. Announces Executive Changes Oct 17
EyePoint Pharmaceuticals, Inc. Reports Positive Masked Safety Update for Lead Product Candidate Eyp-1901 in Ongoing Pavia and Davio 2 Phase 2 Clinical Trials as of September 1, 2023 Sep 12
New minor risk - Shareholder dilution Aug 07
Second quarter 2023 earnings released: US$0.61 loss per share (vs US$0.52 loss in 2Q 2022) Aug 03
EyePoint Pharmaceuticals, Inc. Announces Interim Masked Safety Data and Patient Baseline Characteristics for EYP-1901 Jul 29
EyePoint Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 28 Eyepoint Pharmaceuticals, Inc. Announces Chief Executive Officer Changes
Eyepoint Pharmaceuticals Completes Enrollment in Phase 2 Pavia Clinical Trial of Eyp-1901 in Non-Proliferative Diabetic Retinopathy Jun 06
Alimera Sciences, Inc. entered into an agreement to acquire YUTIQ® from EyePoint Pharmaceuticals, Inc. for $82.5 million. May 19
Now 20% undervalued May 09
First quarter 2023 earnings released: US$0.56 loss per share (vs US$0.56 loss in 1Q 2022) May 03
Full year 2022 earnings released: US$2.74 loss per share (vs US$2.03 loss in FY 2021) Mar 03 EyePoint Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022
Eyepoint Pharmaceuticals Promotes Jay S. Duker, M.D. to President and Chief Operating Officer Jan 05
High number of new directors Nov 17
Third quarter 2022 earnings released: US$0.49 loss per share (vs US$0.58 loss in 3Q 2021) Nov 03
EyePoint Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 27
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathy Sep 30
Second quarter 2022 earnings released: US$0.52 loss per share (vs US$0.35 loss in 2Q 2021) Aug 04
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMD Aug 02
EyePoint Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022 Jul 28
EyePoint Pharmaceuticals, Inc. Announces Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD Jul 16
EyePoint Pharmaceuticals, Inc. Appoints Karen Zaderej to Board of Directors Jul 12
EyePoint Pharmaceuticals Announces Election of Tony Adamis, M.D. to Board of Directors Jun 24 EyePoint Pharmaceuticals, Inc. and OcuMension Therapeutics Announce Approval of New Drug Application by China's NMPA for YUTIQ(R) for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye Jun 22
First quarter 2022 earnings released: US$0.56 loss per share (vs US$0.50 loss in 1Q 2021) May 05
High number of new and inexperienced directors Apr 27
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 04
EyePoint Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 03, 2022 Feb 25
Third quarter 2021 earnings released: US$0.58 loss per share (vs US$0.30 loss in 3Q 2020) Nov 04
EyePoint Pharmaceuticals, Inc. to Present Data At the American Academy of Ophthalmology 2021 Annual Meeting Sep 20
Second quarter 2021 earnings released: US$0.35 loss per share (vs US$1.04 loss in 2Q 2020) Aug 05
High number of new directors Aug 03
Eyepoint Pharmaceuticals, Inc. Announces New Category III CPT Code for DEXYCU® Intraocular Suspension, Approved by the American Medical Association Jul 02
EyePoint Pharmaceuticals Announces Completion of Enrollment of Phase 1 DAVIO Clinical Trial of EYP-1901 for the Potential Treatment of Wet AMD May 26
EyePoint Pharmaceuticals, Inc. announced delayed annual 10-K filing May 04
Full year 2020 earnings released: US$3.54 loss per share (vs US$5.45 loss in FY 2019) Mar 05
Revenue misses expectations Mar 05
EyePoint Pharmaceuticals, Inc. to Report Fiscal Year 2020 Results on Mar 04, 2021 Feb 26
New 90-day high: €12.40 Feb 18
EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $100.1 million. Feb 03
New 90-day high: €9.30 Feb 02
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD Jan 29
EyePoint Pharmaceuticals, Inc. Announces Board Changes Jan 04
New 90-day high: €4.75 Dec 30
EyePoint Pharmaceuticals, Inc. Announces $16.5 Million Monetization of ILUVIEN® Royalty with SWK Holdings Corporation Dec 20 Shareholder Returns PV3B DE Pharmaceuticals DE Market 7D 32.2% 3.4% 2.0% 1Y -54.5% -14.7% 9.6%
See full shareholder returns
Return vs Market: PV3B underperformed the German Market which returned 9.6% over the past year.
Price Volatility Is PV3B's price volatile compared to industry and market? PV3B volatility PV3B Average Weekly Movement 18.3% Pharmaceuticals Industry Average Movement 5.6% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: PV3B's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: PV3B's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME).
Show more EyePoint Pharmaceuticals, Inc. Fundamentals Summary How do EyePoint Pharmaceuticals's earnings and revenue compare to its market cap? PV3B fundamental statistics Market cap €627.08m Earnings (TTM ) -€100.40m Revenue (TTM ) €44.31m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) PV3B income statement (TTM ) Revenue US$45.71m Cost of Revenue US$110.20m Gross Profit -US$64.48m Other Expenses US$39.09m Earnings -US$103.57m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.48 Gross Margin -141.06% Net Profit Margin -226.57% Debt/Equity Ratio 0%
How did PV3B perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/08 01:06 End of Day Share Price 2025/01/08 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources EyePoint Pharmaceuticals, Inc. is covered by 20 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Colleen Kusy Baird Andrew D'Silva B. Riley Securities, Inc. Jennifer Kim Cantor Fitzgerald & Co.
Show 17 more analysts 
